Contineum Therapeutics, Inc.
Company Stats
- Market Cap
- $504.9M
- as of Sep 30, 2026
- Shares Outstanding
- 37.6M
- Free Float
- 85.9%
Income Statement
- Operating Income
- -$68.1M
- Net Income
- -$60.0M
- EBITDA
- -$67.7M
Cash Flow
- Free Cash Flow
- -$55.5M
- FCF Yield
- -11.0%
- Owner FCF Yield
- -13.0%
Balance Sheet
- Cash & Equivalents
- $75.6M
Returns & Capital
- SBC, 3Y Avg
- $6.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$55.5M | — |
| FY2024 | $0 | -$33.4M | — |
| FY2023 | $50.0M | $18.9M | 37.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 5, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back